-$0.34 EPS Expected for Iovance Biotherapeutics Inc (IOVA) This Quarter

Equities analysts forecast that Iovance Biotherapeutics Inc (NASDAQ:IOVA) will post ($0.34) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Iovance Biotherapeutics’ earnings, with estimates ranging from ($0.36) to ($0.30). Iovance Biotherapeutics posted earnings of ($0.31) per share during the same quarter last year, which suggests a negative year over year growth rate of 9.7%. The business is scheduled to issue its next quarterly earnings report on Tuesday, October 30th.

On average, analysts expect that Iovance Biotherapeutics will report full year earnings of ($1.32) per share for the current fiscal year, with EPS estimates ranging from ($1.39) to ($1.24). For the next fiscal year, analysts anticipate that the firm will report earnings of ($1.43) per share, with EPS estimates ranging from ($1.62) to ($1.24). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that cover Iovance Biotherapeutics.

Iovance Biotherapeutics (NASDAQ:IOVA) last released its quarterly earnings results on Monday, August 6th. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.32) by ($0.02).

IOVA has been the topic of a number of recent research reports. ValuEngine upgraded shares of Iovance Biotherapeutics from a “buy” rating to a “strong-buy” rating in a report on Wednesday, May 2nd. BidaskClub cut shares of Iovance Biotherapeutics from a “buy” rating to a “hold” rating in a report on Friday, June 1st. Zacks Investment Research cut shares of Iovance Biotherapeutics from a “hold” rating to a “sell” rating in a report on Thursday, July 12th. HC Wainwright set a $22.00 price objective on shares of Iovance Biotherapeutics and gave the stock a “buy” rating in a report on Wednesday, June 13th. Finally, Chardan Capital reiterated a “buy” rating and set a $30.00 price target on shares of Iovance Biotherapeutics in a report on Friday, July 6th. Two investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. The company has an average rating of “Buy” and an average price target of $22.69.

Iovance Biotherapeutics traded up $0.75, reaching $14.65, during trading on Friday, MarketBeat Ratings reports. The company had a trading volume of 610,945 shares, compared to its average volume of 738,566. Iovance Biotherapeutics has a 52 week low of $4.45 and a 52 week high of $19.90. The company has a market cap of $1.33 billion, a P/E ratio of -10.39 and a beta of 2.72.

Several large investors have recently bought and sold shares of the company. venBio Select Advisor LLC grew its holdings in shares of Iovance Biotherapeutics by 53.8% during the first quarter. venBio Select Advisor LLC now owns 8,078,505 shares of the biotechnology company’s stock valued at $136,527,000 after buying an additional 2,825,055 shares during the last quarter. BlackRock Inc. grew its holdings in shares of Iovance Biotherapeutics by 8.9% during the second quarter. BlackRock Inc. now owns 6,296,691 shares of the biotechnology company’s stock valued at $80,598,000 after buying an additional 512,844 shares during the last quarter. Franklin Resources Inc. grew its holdings in shares of Iovance Biotherapeutics by 6.6% during the first quarter. Franklin Resources Inc. now owns 5,310,163 shares of the biotechnology company’s stock valued at $89,742,000 after buying an additional 330,697 shares during the last quarter. Farallon Capital Management LLC lifted its position in Iovance Biotherapeutics by 122.3% during the first quarter. Farallon Capital Management LLC now owns 4,150,000 shares of the biotechnology company’s stock valued at $70,135,000 after purchasing an additional 2,283,100 shares during the period. Finally, Victory Capital Management Inc. lifted its position in Iovance Biotherapeutics by 2.6% during the second quarter. Victory Capital Management Inc. now owns 2,344,279 shares of the biotechnology company’s stock valued at $30,007,000 after purchasing an additional 58,780 shares during the period. Hedge funds and other institutional investors own 86.53% of the company’s stock.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is LN-144, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors for the treatment of metastatic melanoma.

Recommended Story: Why Dividend Stocks May Be Right for You

Get a free copy of the Zacks research report on Iovance Biotherapeutics (IOVA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Iovance Biotherapeutics (NASDAQ:IOVA)

Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply